首页> 外文期刊>Journal of viral hepatitis. >Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002.
【24h】

Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002.

机译:自2002年以来,减少了与肝脏相关的住院和艾滋病毒感染患者的死亡人数。

获取原文
获取原文并翻译 | 示例
           

摘要

Since the advent of highly active antiretroviral therapy (HAART), complications of chronic liver disease (CLD) have emerged as one of the leading causes of hospital admission and death among HIV-infected patients with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections. The impact of CLD on hospital admissions and deaths in HIV-infected patients attended at one reference HIV hospital in Madrid during the last 9 years was analysed. All clinical charts from January 1996 to December 2004 were retrospectively examined. Demographics, discharge diagnosis, complications during inhospital stay and causes of death were recorded. A total of 2527 hospital admissions in 2008 distinct HIV-infected persons were recorded. Overall, 84% were iv drug users; mean age was 37 years and the mean CD4 count was 224 cells/muL. Both mean age and CD4 count significantly increased during the study period (P < 0.01). Overall, 42% of hospitalized patients were on antiretroviral therapy. Decompensated CLD was the cause of admission and/or developed during hospitalization in 345 patients (14%). Admissions caused by decompensated CLD increased significantly from 9.1% (30/329) in 1996 to 26% (78/294) in 2002. A significant steady decline occurred since then, being 11% (29/253) in the year 2004. Similarly, inhospital liver-related deaths were 9% (5/54) in 1996, peaked to 59% (10/17) in 2001 and declined to 20% (3/15) in the year 2004. Chronic hepatitis C was responsible for admissions and/or deaths in 73.5% of CLD cases. In conclusion, the rate of liver-related hospital admissions and deaths among HIV-infected patients peaked in the year 2002 and has steadily declined since then. A slower progression to liver cirrhosis in patients on HAART, avoidance of hepatotoxic antiretroviral drugs and more frequent use of anti-HCV therapy in HIV/HCV-coinfected patients could account for this benefit.
机译:自高效抗逆转录病毒疗法(HAART)问世以来,慢性肝病(CLD)并发症已成为感染HIV的慢性乙型肝炎病毒(HBV)和/或肝炎患者中住院和死亡的主要原因之一C病毒(HCV)感染。分析了CLD对过去9年在马德里一家参考HIV医院就诊的HIV感染患者的住院人数和死亡的影响。回顾性分析了1996年1月至2004年12月的所有临床图表。记录人口统计学,出院诊断,住院期间的并发症和死亡原因。在2008年,总共记录了2527例住院的不同HIV感染者。总体而言,静脉吸毒者占84%;平均年龄为37岁,平均CD4计数为224细胞/μL。在研究期间,平均年龄和CD4计数均显着增加(P <0.01)。总体而言,有42%的住院患者正在接受抗逆转录病毒治疗。失代偿的CLD是345位患者(14%)住院期间和/或在住院期间发生的原因。由失代偿的CLD导致的入学人数从1996年的9.1%(30/329)大幅增加到2002年的26%(78/294)。此后出现了明显的稳定下降,2004年为11%(29/253)。 ,与医院内肝脏相关的死亡人数在1996年为9%(5/54),在2001年达到59%(10/17)的峰值,并在2004年下降至20%(3/15)。慢性丙型肝炎是导致入院的原因和/或73.5%的CLD病例死亡。总之,在2002年,HIV感染患者的肝脏相关住院和死亡人数达到顶峰,此后一直稳定下降。使用HAART的患者肝硬化进展较慢,避免使用肝毒性抗逆转录病毒药物以及在HIV / HCV合并感染的患者中更频繁地使用抗HCV治疗可以解释这种益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号